ÂÜÀòÂÒÂ×

Glenn Bubley, MD, is a renowned expert in genitourinary (GU) medical oncology with a primary focus on prostate cancer. As director of the multidisciplinary genitourinary cancer program at Beth Israel Deaconess Medical Center (BIDMC) involving medical, surgical and radiation oncologists as well as pathologists and basic scientists, he heads numerous clinical/translational trials.

He is Co-Principal Investigator for the prestigious Prostate SPORE (Specialized Programs of Research Excellence) at the Dana Farber/Harvard Cancer Center. The research is a pilot of the development of an anti-prostate cancer agent specifically targeted to prostate cancer cells. He oversees the Hershey Family Prostate Cancer Tissue Bank and Data base at BIDMC, which has more than 1,000 specimens from prostate cancer patients over the past 13 years and directs interventional research for GU oncology as well, overseeing approximately 13 open trials for patients with prostate or bladder cancer.

Dr. Bubley has authored numerous scientific, research and translation papers and articles in his area of expertise, prostate cancer. He serves as at BIDMC and is Associate Professor of Medicine at Harvard Medical School.